Long-Term Effects of Oxygen Therapy on Death or Hospitalization for Heart Failure in Patients With Suspected Acute Myocardial Infarction
BACKGROUND:In the DETO2X-AMI trial (Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction), we compared supplemental oxygen with ambient air in normoxemic patients presenting with suspected myocardial infarction and found no significant survival benefit at 1 year. However, imp...
Saved in:
| Published in | Circulation (New York, N.Y.) Vol. 138; no. 24; pp. 2754 - 2762 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
by the American College of Cardiology Foundation and the American Heart Association, Inc
2018
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | BACKGROUND:In the DETO2X-AMI trial (Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction), we compared supplemental oxygen with ambient air in normoxemic patients presenting with suspected myocardial infarction and found no significant survival benefit at 1 year. However, important secondary end points were not yet available. We now report the prespecified secondary end points cardiovascular death and the composite of all-cause death and hospitalization for heart failure.
METHODS:In this pragmatic, registry-based randomized clinical trial, we used a nationwide quality registry for coronary care for trial procedures and evaluated end points through the Swedish population registry (mortality), the Swedish inpatient registry (heart failure), and cause of death registry (cardiovascular death). Patients with suspected acute myocardial infarction and oxygen saturation of ≥90% were randomly assigned to receive either supplemental oxygen at 6 L/min for 6 to 12 hours delivered by open face mask or ambient air.
RESULTS:A total of 6629 patients were enrolled. Acute heart failure treatment, left ventricular systolic function assessed by echocardiography, and infarct size measured by high-sensitive cardiac troponin T were similar in the 2 groups during the hospitalization period. All-cause death or hospitalization for heart failure within 1 year after randomization occurred in 8.0% of patients assigned to oxygen and in 7.9% of patients assigned to ambient air (hazard ratio, 0.99; 95% CI, 0.84–1.18; P=0.92). During long-term follow-up (median [range], 2.1 [1.0–3.7] years), the composite end point occurred in 11.2% of patients assigned to oxygen and in 10.8% of patients assigned to ambient air (hazard ratio, 1.02; 95% CI, 0.88–1.17; P=0.84), and cardiovascular death occurred in 5.2% of patients assigned to oxygen and in 4.8% assigned to ambient air (hazard ratio, 1.07; 95% CI, 0.87–1.33; P=0.52). The results were consistent across all predefined subgroups.
CONCLUSIONS:Routine use of supplemental oxygen in normoxemic patients with suspected myocardial infarction was not found to reduce the composite of all-cause mortality and hospitalization for heart failure, or cardiovascular death within 1 year or during long-term follow-up.
CLINICAL TRIAL REGISTRATION:URLhttps://www.clinicaltrials.gov. Unique identifierNCT01787110. |
|---|---|
| AbstractList | BACKGROUND: In the DETO2X-AMI trial (Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction), we compared supplemental oxygen with ambient air in normoxemic patients presenting with suspected myocardial infarction and found no significant survival benefit at 1 year. However, important secondary end points were not yet available. We now report the prespecified secondary end points cardiovascular death and the composite of all-cause death and hospitalization for heart failure. METHODS: In this pragmatic, registry-based randomized clinical trial, we used a nationwide quality registry for coronary care for trial procedures and evaluated end points through the Swedish population registry (mortality), the Swedish inpatient registry (heart failure), and cause of death registry (cardiovascular death). Patients with suspected acute myocardial infarction and oxygen saturation of >= 90% were randomly assigned to receive either supplemental oxygen at 6 L/min for 6 to 12 hours delivered by open face mask or ambient air. RESULTS: A total of 6629 patients were enrolled. Acute heart failure treatment, left ventricular systolic function assessed by echocardiography, and infarct size measured by high-sensitive cardiac troponin T were similar in the 2 groups during the hospitalization period. All-cause death or hospitalization for heart failure within 1 year after randomization occurred in 8.0% of patients assigned to oxygen and in 7.9% of patients assigned to ambient air (hazard ratio, 0.99; 95% CI, 0.84-1.18; P=0.92). During long-term follow-up (median [range], 2.1 [1.0-3.7] years), the composite end point occurred in 11.2% of patients assigned to oxygen and in 10.8% of patients assigned to ambient air (hazard ratio, 1.02; 95% CI, 0.88-1.17; P=0.84), and cardiovascular death occurred in 5.2% of patients assigned to oxygen and in 4.8% assigned to ambient air (hazard ratio, 1.07; 95% CI, 0.87-1.33; P=0.52). The results were consistent across all predefined subgroups. CONCLUSIONS: Routine use of supplemental oxygen in normoxemic patients with suspected myocardial infarction was not found to reduce the composite of all-cause mortality and hospitalization for heart failure, or cardiovascular death within 1 year or during long-term follow-up. Background: In the DETO2X-AMI trial (Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction), we compared supplemental oxygen with ambient air in normoxemic patients presenting with suspected myocardial infarction and found no significant survival benefit at 1 year. However, important secondary end points were not yet available. We now report the prespecified secondary end points cardiovascular death and the composite of all-cause death and hospitalization for heart failure. Methods: In this pragmatic, registry-based randomized clinical trial, we used a nationwide quality registry for coronary care for trial procedures and evaluated end points through the Swedish population registry (mortality), the Swedish inpatient registry (heart failure), and cause of death registry (cardiovascular death). Patients with suspected acute myocardial infarction and oxygen saturation of ≥90% were randomly assigned to receive either supplemental oxygen at 6 L/min for 6 to 12 hours delivered by open face mask or ambient air. Results: A total of 6629 patients were enrolled. Acute heart failure treatment, left ventricular systolic function assessed by echocardiography, and infarct size measured by high-sensitive cardiac troponin T were similar in the 2 groups during the hospitalization period. All-cause death or hospitalization for heart failure within 1 year after randomization occurred in 8.0% of patients assigned to oxygen and in 7.9% of patients assigned to ambient air (hazard ratio, 0.99; 95% CI, 0.84–1.18; P =0.92). During long-term follow-up (median [range], 2.1 [1.0–3.7] years), the composite end point occurred in 11.2% of patients assigned to oxygen and in 10.8% of patients assigned to ambient air (hazard ratio, 1.02; 95% CI, 0.88–1.17; P =0.84), and cardiovascular death occurred in 5.2% of patients assigned to oxygen and in 4.8% assigned to ambient air (hazard ratio, 1.07; 95% CI, 0.87–1.33; P =0.52). The results were consistent across all predefined subgroups. Conclusions: Routine use of supplemental oxygen in normoxemic patients with suspected myocardial infarction was not found to reduce the composite of all-cause mortality and hospitalization for heart failure, or cardiovascular death within 1 year or during long-term follow-up. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01787110. In the DETO2X-AMI trial (Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction), we compared supplemental oxygen with ambient air in normoxemic patients presenting with suspected myocardial infarction and found no significant survival benefit at 1 year. However, important secondary end points were not yet available. We now report the prespecified secondary end points cardiovascular death and the composite of all-cause death and hospitalization for heart failure. In this pragmatic, registry-based randomized clinical trial, we used a nationwide quality registry for coronary care for trial procedures and evaluated end points through the Swedish population registry (mortality), the Swedish inpatient registry (heart failure), and cause of death registry (cardiovascular death). Patients with suspected acute myocardial infarction and oxygen saturation of ≥90% were randomly assigned to receive either supplemental oxygen at 6 L/min for 6 to 12 hours delivered by open face mask or ambient air. A total of 6629 patients were enrolled. Acute heart failure treatment, left ventricular systolic function assessed by echocardiography, and infarct size measured by high-sensitive cardiac troponin T were similar in the 2 groups during the hospitalization period. All-cause death or hospitalization for heart failure within 1 year after randomization occurred in 8.0% of patients assigned to oxygen and in 7.9% of patients assigned to ambient air (hazard ratio, 0.99; 95% CI, 0.84–1.18; P=0.92). During long-term follow-up (median [range], 2.1 [1.0–3.7] years), the composite end point occurred in 11.2% of patients assigned to oxygen and in 10.8% of patients assigned to ambient air (hazard ratio, 1.02; 95% CI, 0.88–1.17; P=0.84), and cardiovascular death occurred in 5.2% of patients assigned to oxygen and in 4.8% assigned to ambient air (hazard ratio, 1.07; 95% CI, 0.87–1.33; P=0.52). The results were consistent across all predefined subgroups. Routine use of supplemental oxygen in normoxemic patients with suspected myocardial infarction was not found to reduce the composite of all-cause mortality and hospitalization for heart failure, or cardiovascular death within 1 year or during long-term follow-up. URL: https://www.clinicaltrials.gov. Unique identifier: NCT01787110. Background: In the DETO2X-AMI trial (Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction), we compared supplemental oxygen with ambient air in normoxemic patients presenting with suspected myocardial infarction and found no significant survival benefit at 1 year. However, important secondary end points were not yet available. We now report the prespecified secondary end points cardiovascular death and the composite of all-cause death and hospitalization for heart failure. Methods: In this pragmatic, registry-based randomized clinical trial, we used a nationwide quality registry for coronary care for trial procedures and evaluated end points through the Swedish population registry (mortality), the Swedish inpatient registry (heart failure), and cause of death registry (cardiovascular death). Patients with suspected acute myocardial infarction and oxygen saturation of ≥90% were randomly assigned to receive either supplemental oxygen at 6 L/min for 6 to 12 hours delivered by open face mask or ambient air. Results: A total of 6629 patients were enrolled. Acute heart failure treatment, left ventricular systolic function assessed by echocardiography, and infarct size measured by high-sensitive cardiac troponin T were similar in the 2 groups during the hospitalization period. All-cause death or hospitalization for heart failure within 1 year after randomization occurred in 8.0% of patients assigned to oxygen and in 7.9% of patients assigned to ambient air (hazard ratio, 0.99; 95% CI, 0.84–1.18; P=0.92). During long-term follow-up (median [range], 2.1 [1.0–3.7] years), the composite end point occurred in 11.2% of patients assigned to oxygen and in 10.8% of patients assigned to ambient air (hazard ratio, 1.02; 95% CI, 0.88–1.17; P=0.84), and cardiovascular death occurred in 5.2% of patients assigned to oxygen and in 4.8% assigned to ambient air (hazard ratio, 1.07; 95% CI, 0.87–1.33; P=0.52). The results were consistent across all predefined subgroups. Conclusions: Routine use of supplemental oxygen in normoxemic patients with suspected myocardial infarction was not found to reduce the composite of all-cause mortality and hospitalization for heart failure, or cardiovascular death within 1 year or during long-term follow-up. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01787110. BACKGROUND: In the DETO2X-AMI trial (Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction), we compared supplemental oxygen with ambient air in normoxemic patients presenting with suspected myocardial infarction and found no significant survival benefit at 1 year. However, important secondary end points were not yet available. We now report the prespecified secondary end points cardiovascular death and the composite of all-cause death and hospitalization for heart failure. METHODS: In this pragmatic, registry-based randomized clinical trial, we used a nationwide quality registry for coronary care for trial procedures and evaluated end points through the Swedish population registry (mortality), the Swedish inpatient registry (heart failure), and cause of death registry (cardiovascular death). Patients with suspected acute myocardial infarction and oxygen saturation of >= 90% were randomly assigned to receive either supplemental oxygen at 6 L/min for 6 to 12 hours delivered by open face mask or ambient air. RESULTS: A total of 6629 patients were enrolled. Acute heart failure treatment, left ventricular systolic function assessed by echocardiography, and infarct size measured by high-sensitive cardiac troponin T were similar in the 2 groups during the hospitalization period. All-cause death or hospitalization for heart failure within 1 year after randomization occurred in 8.0% of patients assigned to oxygen and in 7.9% of patients assigned to ambient air (hazard ratio, 0.99; 95% CI, 0.84-1.18; P=0.92). During long-term follow-up (median [range], 2.1 [1.0-3.7] years), the composite end point occurred in 11.2% of patients assigned to oxygen and in 10.8% of patients assigned to ambient air (hazard ratio, 1.02; 95% CI, 0.88-1.17; P=0.84), and cardiovascular death occurred in 5.2% of patients assigned to oxygen and in 4.8% assigned to ambient air (hazard ratio, 1.07; 95% CI, 0.87-1.33; P=0.52). The results were consistent across all predefined subgroups. CONCLUSIONS: Routine use of supplemental oxygen in normoxemic patients with suspected myocardial infarction was not found to reduce the composite of all-cause mortality and hospitalization for heart failure, or cardiovascular death within 1 year or during long-term follow-up. BACKGROUND: In the DETO2X-AMI trial (Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction), we compared supplemental oxygen with ambient air in normoxemic patients presenting with suspected myocardial infarction and found no significant survival benefit at 1 year. However, important secondary end points were not yet available. We now report the prespecified secondary end points cardiovascular death and the composite of all-cause death and hospitalization for heart failure. METHODS: In this pragmatic, registry-based randomized clinical trial, we used a nationwide quality registry for coronary care for trial procedures and evaluated end points through the Swedish population registry (mortality), the Swedish inpatient registry (heart failure), and cause of death registry (cardiovascular death). Patients with suspected acute myocardial infarction and oxygen saturation of amp;gt;= 90% were randomly assigned to receive either supplemental oxygen at 6 L/min for 6 to 12 hours delivered by open face mask or ambient air. RESULTS: A total of 6629 patients were enrolled. Acute heart failure treatment, left ventricular systolic function assessed by echocardiography, and infarct size measured by high-sensitive cardiac troponin T were similar in the 2 groups during the hospitalization period. All-cause death or hospitalization for heart failure within 1 year after randomization occurred in 8.0% of patients assigned to oxygen and in 7.9% of patients assigned to ambient air (hazard ratio, 0.99; 95% CI, 0.84-1.18; P=0.92). During long-term follow-up (median [range], 2.1 [1.0-3.7] years), the composite end point occurred in 11.2% of patients assigned to oxygen and in 10.8% of patients assigned to ambient air (hazard ratio, 1.02; 95% CI, 0.88-1.17; P=0.84), and cardiovascular death occurred in 5.2% of patients assigned to oxygen and in 4.8% assigned to ambient air (hazard ratio, 1.07; 95% CI, 0.87-1.33; P=0.52). The results were consistent across all predefined subgroups. CONCLUSIONS: Routine use of supplemental oxygen in normoxemic patients with suspected myocardial infarction was not found to reduce the composite of all-cause mortality and hospitalization for heart failure, or cardiovascular death within 1 year or during long-term follow-up. BACKGROUND:In the DETO2X-AMI trial (Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction), we compared supplemental oxygen with ambient air in normoxemic patients presenting with suspected myocardial infarction and found no significant survival benefit at 1 year. However, important secondary end points were not yet available. We now report the prespecified secondary end points cardiovascular death and the composite of all-cause death and hospitalization for heart failure. METHODS:In this pragmatic, registry-based randomized clinical trial, we used a nationwide quality registry for coronary care for trial procedures and evaluated end points through the Swedish population registry (mortality), the Swedish inpatient registry (heart failure), and cause of death registry (cardiovascular death). Patients with suspected acute myocardial infarction and oxygen saturation of ≥90% were randomly assigned to receive either supplemental oxygen at 6 L/min for 6 to 12 hours delivered by open face mask or ambient air. RESULTS:A total of 6629 patients were enrolled. Acute heart failure treatment, left ventricular systolic function assessed by echocardiography, and infarct size measured by high-sensitive cardiac troponin T were similar in the 2 groups during the hospitalization period. All-cause death or hospitalization for heart failure within 1 year after randomization occurred in 8.0% of patients assigned to oxygen and in 7.9% of patients assigned to ambient air (hazard ratio, 0.99; 95% CI, 0.84–1.18; P=0.92). During long-term follow-up (median [range], 2.1 [1.0–3.7] years), the composite end point occurred in 11.2% of patients assigned to oxygen and in 10.8% of patients assigned to ambient air (hazard ratio, 1.02; 95% CI, 0.88–1.17; P=0.84), and cardiovascular death occurred in 5.2% of patients assigned to oxygen and in 4.8% assigned to ambient air (hazard ratio, 1.07; 95% CI, 0.87–1.33; P=0.52). The results were consistent across all predefined subgroups. CONCLUSIONS:Routine use of supplemental oxygen in normoxemic patients with suspected myocardial infarction was not found to reduce the composite of all-cause mortality and hospitalization for heart failure, or cardiovascular death within 1 year or during long-term follow-up. CLINICAL TRIAL REGISTRATION:URLhttps://www.clinicaltrials.gov. Unique identifierNCT01787110. In the DETO2X-AMI trial (Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction), we compared supplemental oxygen with ambient air in normoxemic patients presenting with suspected myocardial infarction and found no significant survival benefit at 1 year. However, important secondary end points were not yet available. We now report the prespecified secondary end points cardiovascular death and the composite of all-cause death and hospitalization for heart failure.BackgroundIn the DETO2X-AMI trial (Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction), we compared supplemental oxygen with ambient air in normoxemic patients presenting with suspected myocardial infarction and found no significant survival benefit at 1 year. However, important secondary end points were not yet available. We now report the prespecified secondary end points cardiovascular death and the composite of all-cause death and hospitalization for heart failure.In this pragmatic, registry-based randomized clinical trial, we used a nationwide quality registry for coronary care for trial procedures and evaluated end points through the Swedish population registry (mortality), the Swedish inpatient registry (heart failure), and cause of death registry (cardiovascular death). Patients with suspected acute myocardial infarction and oxygen saturation of ≥90% were randomly assigned to receive either supplemental oxygen at 6 L/min for 6 to 12 hours delivered by open face mask or ambient air.MethodsIn this pragmatic, registry-based randomized clinical trial, we used a nationwide quality registry for coronary care for trial procedures and evaluated end points through the Swedish population registry (mortality), the Swedish inpatient registry (heart failure), and cause of death registry (cardiovascular death). Patients with suspected acute myocardial infarction and oxygen saturation of ≥90% were randomly assigned to receive either supplemental oxygen at 6 L/min for 6 to 12 hours delivered by open face mask or ambient air.A total of 6629 patients were enrolled. Acute heart failure treatment, left ventricular systolic function assessed by echocardiography, and infarct size measured by high-sensitive cardiac troponin T were similar in the 2 groups during the hospitalization period. All-cause death or hospitalization for heart failure within 1 year after randomization occurred in 8.0% of patients assigned to oxygen and in 7.9% of patients assigned to ambient air (hazard ratio, 0.99; 95% CI, 0.84–1.18; P=0.92). During long-term follow-up (median [range], 2.1 [1.0–3.7] years), the composite end point occurred in 11.2% of patients assigned to oxygen and in 10.8% of patients assigned to ambient air (hazard ratio, 1.02; 95% CI, 0.88–1.17; P=0.84), and cardiovascular death occurred in 5.2% of patients assigned to oxygen and in 4.8% assigned to ambient air (hazard ratio, 1.07; 95% CI, 0.87–1.33; P=0.52). The results were consistent across all predefined subgroups.ResultsA total of 6629 patients were enrolled. Acute heart failure treatment, left ventricular systolic function assessed by echocardiography, and infarct size measured by high-sensitive cardiac troponin T were similar in the 2 groups during the hospitalization period. All-cause death or hospitalization for heart failure within 1 year after randomization occurred in 8.0% of patients assigned to oxygen and in 7.9% of patients assigned to ambient air (hazard ratio, 0.99; 95% CI, 0.84–1.18; P=0.92). During long-term follow-up (median [range], 2.1 [1.0–3.7] years), the composite end point occurred in 11.2% of patients assigned to oxygen and in 10.8% of patients assigned to ambient air (hazard ratio, 1.02; 95% CI, 0.88–1.17; P=0.84), and cardiovascular death occurred in 5.2% of patients assigned to oxygen and in 4.8% assigned to ambient air (hazard ratio, 1.07; 95% CI, 0.87–1.33; P=0.52). The results were consistent across all predefined subgroups.Routine use of supplemental oxygen in normoxemic patients with suspected myocardial infarction was not found to reduce the composite of all-cause mortality and hospitalization for heart failure, or cardiovascular death within 1 year or during long-term follow-up.ConclusionsRoutine use of supplemental oxygen in normoxemic patients with suspected myocardial infarction was not found to reduce the composite of all-cause mortality and hospitalization for heart failure, or cardiovascular death within 1 year or during long-term follow-up.URL: https://www.clinicaltrials.gov. Unique identifier: NCT01787110.Clinical Trial RegistrationURL: https://www.clinicaltrials.gov. Unique identifier: NCT01787110. |
| Author | Ljung, Lina Sparv, David James, Stefan K. Jumatate, Raluca Östlund, Ollie Pernow, John Lindahl, Bertil Omerovic, Elmir Herlitz, Johan Lauermann, Jörg Lingman, Markus Engström, Anders Lindmark, Krister Nilsson, Carina Jernberg, Tomas Kellerth, Thomas Alfredsson, Joakim Berglund, Ellinor Erlinge, David Ravn-Fischer, Annica Hofmann, Robin Bergström, Olle Yndigegn, Troels |
| AuthorAffiliation | Department of Clinical Sciences, Division of Cardiology, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden (T.J.). Department of Medical Sciences, Cardiology (B.L., S.K.J.), Uppsala University, Sweden. Uppsala Clinical Research Center (B.L., O.O., S.K.J.), Uppsala University, Sweden. Department of Medical and Health Sciences and Department of Cardiology, Linköping University, Sweden (J.A.). Department of Medicine, Solna, Centre for Resuscitation Science, Karolinska Institutet, Stockholm, Sweden (E.B.). Department of Medicine, Växjö Hospital, Sweden (O.B.). Department of Medicine, Division of Cardiology, Kalmar Regional Hospital, Sweden (A.E.). Department of Clinical Sciences, Cardiology, Lund University, Sweden (D.E., D.S., T.Y.). Department of Molecular and Clinical Medicine and Sahlgrenska University Hospital, Department of Cardiology, University of Gothenburg, Sweden (J.H., E.O., A.R.-F.). Department of Health Sciences, University of Borås, Sweden (J.H.). Department of Med |
| AuthorAffiliation_xml | – name: Department of Clinical Sciences, Division of Cardiology, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden (T.J.). Department of Medical Sciences, Cardiology (B.L., S.K.J.), Uppsala University, Sweden. Uppsala Clinical Research Center (B.L., O.O., S.K.J.), Uppsala University, Sweden. Department of Medical and Health Sciences and Department of Cardiology, Linköping University, Sweden (J.A.). Department of Medicine, Solna, Centre for Resuscitation Science, Karolinska Institutet, Stockholm, Sweden (E.B.). Department of Medicine, Växjö Hospital, Sweden (O.B.). Department of Medicine, Division of Cardiology, Kalmar Regional Hospital, Sweden (A.E.). Department of Clinical Sciences, Cardiology, Lund University, Sweden (D.E., D.S., T.Y.). Department of Molecular and Clinical Medicine and Sahlgrenska University Hospital, Department of Cardiology, University of Gothenburg, Sweden (J.H., E.O., A.R.-F.). Department of Health Sciences, University of Borås, Sweden (J.H.). Department of Medicine, Kristianstad Hospital, Sweden (R.J.). Department of Cardiology, Örebro University Hospital, Sweden (T.K.). Department of Internal Medicine, Division of Cardiology, Ryhov Hospital, Jönköping, Sweden (J.L.). Department of Public Health and Clinical Medicine, Umeå University, Sweden (K.L.). Department of Medicine, Halland Hospital, Halmstad, Sweden (M.L.). Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden (M.L.). Department of Clinical Science and Education, Division of Cardiology, Karolinska Institutet, Södersjukhuset, Stockholm, Sweden (L.L., R.F.). Department of Medicine, Ljungby Hospital, Sweden (C.N.). Department of Medicine, Division of Cardiology, Karolinska Institutet, Solna, and Karolinska University Hospital, Stockholm, Sweden (J.P.) |
| Author_xml | – sequence: 1 givenname: Tomas surname: Jernberg fullname: Jernberg, Tomas organization: Department of Clinical Sciences, Division of Cardiology, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden (T.J.). Department of Medical Sciences, Cardiology (B.L., S.K.J.), Uppsala University, Sweden. Uppsala Clinical Research Center (B.L., O.O., S.K.J.), Uppsala University, Sweden. Department of Medical and Health Sciences and Department of Cardiology, Linköping University, Sweden (J.A.). Department of Medicine, Solna, Centre for Resuscitation Science, Karolinska Institutet, Stockholm, Sweden (E.B.). Department of Medicine, Växjö Hospital, Sweden (O.B.). Department of Medicine, Division of Cardiology, Kalmar Regional Hospital, Sweden (A.E.). Department of Clinical Sciences, Cardiology, Lund University, Sweden (D.E., D.S., T.Y.). Department of Molecular and Clinical Medicine and Sahlgrenska University Hospital, Department of Cardiology, University of Gothenburg, Sweden (J.H., E.O., A.R.-F.). Department of Health Sciences, University of Borås, Sweden (J.H.). Department of Medicine, Kristianstad Hospital, Sweden (R.J.). Department of Cardiology, Örebro University Hospital, Sweden (T.K.). Department of Internal Medicine, Division of Cardiology, Ryhov Hospital, Jönköping, Sweden (J.L.). Department of Public Health and Clinical Medicine, Umeå University, Sweden (K.L.). Department of Medicine, Halland Hospital, Halmstad, Sweden (M.L.). Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden (M.L.). Department of Clinical Science and Education, Division of Cardiology, Karolinska Institutet, Södersjukhuset, Stockholm, Sweden (L.L., R.F.). Department of Medicine, Ljungby Hospital, Sweden (C.N.). Department of Medicine, Division of Cardiology, Karolinska Institutet, Solna, and Karolinska University Hospital, Stockholm, Sweden (J.P.) – sequence: 2 givenname: Bertil surname: Lindahl fullname: Lindahl, Bertil – sequence: 3 givenname: Joakim surname: Alfredsson fullname: Alfredsson, Joakim – sequence: 4 givenname: Ellinor surname: Berglund fullname: Berglund, Ellinor – sequence: 5 givenname: Olle surname: Bergström fullname: Bergström, Olle – sequence: 6 givenname: Anders surname: Engström fullname: Engström, Anders – sequence: 7 givenname: David surname: Erlinge fullname: Erlinge, David – sequence: 8 givenname: Johan surname: Herlitz fullname: Herlitz, Johan – sequence: 9 givenname: Raluca surname: Jumatate fullname: Jumatate, Raluca – sequence: 10 givenname: Thomas surname: Kellerth fullname: Kellerth, Thomas – sequence: 11 givenname: Jörg surname: Lauermann fullname: Lauermann, Jörg – sequence: 12 givenname: Krister surname: Lindmark fullname: Lindmark, Krister – sequence: 13 givenname: Markus surname: Lingman fullname: Lingman, Markus – sequence: 14 givenname: Lina surname: Ljung fullname: Ljung, Lina – sequence: 15 givenname: Carina surname: Nilsson fullname: Nilsson, Carina – sequence: 16 givenname: Elmir surname: Omerovic fullname: Omerovic, Elmir – sequence: 17 givenname: John surname: Pernow fullname: Pernow, John – sequence: 18 givenname: Annica surname: Ravn-Fischer fullname: Ravn-Fischer, Annica – sequence: 19 givenname: David surname: Sparv fullname: Sparv, David – sequence: 20 givenname: Troels surname: Yndigegn fullname: Yndigegn, Troels – sequence: 21 givenname: Ollie surname: Östlund fullname: Östlund, Ollie – sequence: 22 givenname: Stefan surname: James middlename: K. fullname: James, Stefan K. – sequence: 23 givenname: Robin surname: Hofmann fullname: Hofmann, Robin |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30767504$$D View this record in MEDLINE/PubMed https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-153672$$DView record from Swedish Publication Index https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-154871$$DView record from Swedish Publication Index https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-372939$$DView record from Swedish Publication Index https://gup.ub.gu.se/publication/275701$$DView record from Swedish Publication Index https://lup.lub.lu.se/record/737e0361-29fb-4699-9683-73f603c02116$$DView record from Swedish Publication Index oai:portal.research.lu.se:publications/737e0361-29fb-4699-9683-73f603c02116$$DView record from Swedish Publication Index http://kipublications.ki.se/Default.aspx?queryparsed=id:139760112$$DView record from Swedish Publication Index |
| BookMark | eNqNk11v0zAUhiM0xD7gL6BwxwUZ_ojj-ApV3UYrFYqgg0vLcU_asDQOdqJRfgE_m5O1A4FUtIsoyevnvEc-H6fRUeMaiKIXlJxTmtHX4-nH8fVstJjO348mI9Tyc8Izxsij6IQKliap4OooOiGEqERyxo6j0xC-4m_GpXgSHXMiMylIehL9nLlmlSzAb-LLsgTbhdiV8fz7dgVNvFiDN-02dk18AaZbx87HExfaqjN19cN0FR6UgwbGd_GVqereQ1w18Qc8gwa9vlQY9akPLTrDMh7ZvoP43dZZ45eVqeNpUxpvB6On0ePS1AGe7d9n0fXV5WI8SWbzt9PxaJZYmVGRFEBEqQpRCmIlCCbwHpBJKDNZWEV4mYuCpBkrjLGQ56klRkljhFVsqSQofhYlO99wC21f6NZXG-O32plK76Ub_AKd5lQJhrw5yLfOYyW0h4AFsGtd90MgUnVl76oTtOQSsDdUM1UWOs2U0irLOeplRrglDBuKOWYHc9R9i0-x936g3eErrtAOpdWdG5NCEor8q4P8RfV5pJ1f6b7XXDLF_1_BP_im11SkuaQP4-tq4Hkmh4q_3PGtd996CJ3eVMFCXZsGXB80ozmneZazAX2-R_tiA8vf1vfzjcCbHWC9C8FDqS0O79CazuO4akr0sFH6741CLde7jUIH9Y_DfZKHxKa72FtXd-DDTd3fgtdrMHW31riOhBMqE0ZoTrFzJBkkwX8BCQY4gw |
| CitedBy_id | crossref_primary_10_1016_j_ahj_2021_03_001 crossref_primary_10_1038_s41569_023_00886_y crossref_primary_10_1016_j_ijcard_2020_10_077 crossref_primary_10_3389_fcvm_2021_638829 crossref_primary_10_1177_2048872619848978 crossref_primary_10_1016_j_jcin_2019_09_016 crossref_primary_10_1016_j_jjcc_2023_10_006 crossref_primary_10_4103_2221_6189_374309 crossref_primary_10_1016_j_chest_2020_07_015 crossref_primary_10_2147_IJGM_S349722 crossref_primary_10_1016_j_sleep_2021_01_007 crossref_primary_10_3389_fpubh_2021_711222 crossref_primary_10_1007_s12471_022_01752_1 crossref_primary_10_1136_heartjnl_2021_320151 crossref_primary_10_1111_joim_13272 crossref_primary_10_1186_s40779_021_00330_7 crossref_primary_10_2337_dc19_0590 crossref_primary_10_1007_s10741_022_10216_y crossref_primary_10_3390_hearts5010010 crossref_primary_10_1186_s13063_022_06101_6 crossref_primary_10_1253_circrep_CR_22_0031 |
| Cites_doi | 10.1016/j.ahj.2013.09.022 10.1001/jama.2017.11463 10.1093/eurheartj/ehy326 10.1136/hrt.2010.198804 10.1016/S0140-6736(16)31012-1 10.1186/1471-2458-11-450 10.1016/0002-8703(95)90194-9 10.1136/heartjnl-2017–312322 10.1093/eurheartj/eht110 10.1016/S0140-6736(18)30479-3 10.1007/s10654-016-0117-y 10.1093/eurheartj/ehs184 10.1161/CIRCULATIONAHA.117.030798 10.1161/01.CIR.52.3.360 10.1016/j.jacc.2016.01.069 10.1161/CIRCULATIONAHA.117.031664 10.1161/CIRCULATIONAHA.114.014494 10.1056/NEJMe1709250 10.1007/s00134-017-4739-7 10.1136/heartjnl-2018–313089 10.1111/joim.12716 10.1016/j.jacc.2015.10.005 10.1016/j.jacc.2006.03.034 10.1161/CIR.0000000000000133 10.1056/NEJMra1112570 10.1016/j.jacc.2010.04.052 10.1016/j.jchf.2016.03.026 10.1056/NEJMoa1706222 10.1136/hrt.2006.112508 10.1161/01.CIR.53.3.411 10.1093/eurheartj/ehx393 10.1016/j.resuscitation.2018.04.027 |
| ContentType | Journal Article |
| Contributor | Carlsson, Jorg Pourbazargan, Melvin Lindmark, Krister Erlandsson, Marianne Omerovic, Elmer Kellerth, Thomas Risenfors, Martin Frick, Mats Alfredsson, Joakim Bystrom, Bjorn Jumatate, Raluca Hoffmann, Robin Svensson, Leif Wallstrom, Yiwa Serrander, Martin Lingman, Markus Kastberg, Robert Arefalk, Gabriel Engstrom, Anders Linder, Rickard Jernberg, Tomas Barmano, Neshro Nilsson, Lennart Malmqvist, Lennart Angeras, Oskar Forsman, Lena Sparv, David Peterson, Magnus Pettersson, Tommy Digerfeldt, Christofer James, Stefan Ekstrom, Mattias Karlsson, Jan-Erik Lauermann, Jorg Witt, Nils Mellbin, Linda Haaga, Urban Hornestam, Bjorn Pernow, John Lindahl, Bertil RavnFischer, Annica Bergstrom, Olle Herlitz, Johan Haugen, Espen Lagerqvist, Bo Verouhis, Dinos Erlinge, David Berglund, Ellinor Millbourn, Anna Eriksson, Gull-Britt Yndigegn, Troels Kjellberg, Fredrik |
| Contributor_xml | – sequence: 1 givenname: Rickard surname: Linder fullname: Linder, Rickard – sequence: 2 givenname: Mattias surname: Ekstrom fullname: Ekstrom, Mattias – sequence: 3 givenname: Lena surname: Forsman fullname: Forsman, Lena – sequence: 4 givenname: Johan surname: Herlitz fullname: Herlitz, Johan – sequence: 5 givenname: Annica surname: RavnFischer fullname: RavnFischer, Annica – sequence: 6 givenname: Elmer surname: Omerovic fullname: Omerovic, Elmer – sequence: 7 givenname: Oskar surname: Angeras fullname: Angeras, Oskar – sequence: 8 givenname: Bjorn surname: Hornestam fullname: Hornestam, Bjorn – sequence: 9 givenname: Robert surname: Kastberg fullname: Kastberg, Robert – sequence: 10 givenname: Espen surname: Haugen fullname: Haugen, Espen – sequence: 11 givenname: Markus surname: Lingman fullname: Lingman, Markus – sequence: 12 givenname: Anna surname: Millbourn fullname: Millbourn, Anna – sequence: 13 givenname: Anders surname: Engstrom fullname: Engstrom, Anders – sequence: 14 givenname: Jorg surname: Carlsson fullname: Carlsson, Jorg – sequence: 15 givenname: Urban surname: Haaga fullname: Haaga, Urban – sequence: 16 givenname: Tomas surname: Jernberg fullname: Jernberg, Tomas – sequence: 17 givenname: John surname: Pernow fullname: Pernow, John – sequence: 18 givenname: Linda surname: Mellbin fullname: Mellbin, Linda – sequence: 19 givenname: Dinos surname: Verouhis fullname: Verouhis, Dinos – sequence: 20 givenname: Fredrik surname: Kjellberg fullname: Kjellberg, Fredrik – sequence: 21 givenname: Raluca surname: Jumatate fullname: Jumatate, Raluca – sequence: 22 givenname: Lennart surname: Malmqvist fullname: Malmqvist, Lennart – sequence: 23 givenname: Gull-Britt surname: Eriksson fullname: Eriksson, Gull-Britt – sequence: 24 givenname: Thomas surname: Kellerth fullname: Kellerth, Thomas – sequence: 25 givenname: Joakim surname: Alfredsson fullname: Alfredsson, Joakim – sequence: 26 givenname: Lennart surname: Nilsson fullname: Nilsson, Lennart – sequence: 27 givenname: Krister surname: Lindmark fullname: Lindmark, Krister – sequence: 28 givenname: Tommy surname: Pettersson fullname: Pettersson, Tommy – sequence: 29 givenname: Melvin surname: Pourbazargan fullname: Pourbazargan, Melvin – sequence: 30 givenname: Martin surname: Serrander fullname: Serrander, Martin – sequence: 31 givenname: Jorg surname: Lauermann fullname: Lauermann, Jorg – sequence: 32 givenname: Jan-Erik surname: Karlsson fullname: Karlsson, Jan-Erik – sequence: 33 givenname: Neshro surname: Barmano fullname: Barmano, Neshro – sequence: 34 givenname: Martin surname: Risenfors fullname: Risenfors, Martin – sequence: 35 givenname: Magnus surname: Peterson fullname: Peterson, Magnus – sequence: 36 givenname: Yiwa surname: Wallstrom fullname: Wallstrom, Yiwa – sequence: 37 givenname: David surname: Erlinge fullname: Erlinge, David – sequence: 38 givenname: David surname: Sparv fullname: Sparv, David – sequence: 39 givenname: Marianne surname: Erlandsson fullname: Erlandsson, Marianne – sequence: 40 givenname: Robin surname: Hoffmann fullname: Hoffmann, Robin – sequence: 41 givenname: Nils surname: Witt fullname: Witt, Nils – sequence: 42 givenname: Mats surname: Frick fullname: Frick, Mats – sequence: 43 givenname: Leif surname: Svensson fullname: Svensson, Leif – sequence: 44 givenname: Ellinor surname: Berglund fullname: Berglund, Ellinor – sequence: 45 givenname: Troels surname: Yndigegn fullname: Yndigegn, Troels – sequence: 46 givenname: Stefan surname: James fullname: James, Stefan – sequence: 47 givenname: Bertil surname: Lindahl fullname: Lindahl, Bertil – sequence: 48 givenname: Gabriel surname: Arefalk fullname: Arefalk, Gabriel – sequence: 49 givenname: Bo surname: Lagerqvist fullname: Lagerqvist, Bo – sequence: 50 givenname: Christofer surname: Digerfeldt fullname: Digerfeldt, Christofer – sequence: 51 givenname: Olle surname: Bergstrom fullname: Bergstrom, Olle – sequence: 52 givenname: Bjorn surname: Bystrom fullname: Bystrom, Bjorn |
| Copyright | 2018 by the American College of Cardiology Foundation and the American Heart Association, Inc. 2018 American Heart Association, Inc. |
| Copyright_xml | – notice: 2018 by the American College of Cardiology Foundation and the American Heart Association, Inc. – notice: 2018 American Heart Association, Inc. |
| CorporateAuthor | For the DETO2X-SWEDEHEART Investigators DETO2X-SWEDEHEART Investigators Kardiologi Department of Clinical Sciences, Lund Molekylär kardiologi Molecular Cardiology Faculty of Medicine Institutionen för kliniska vetenskaper, Lund Sektion II Section II Lunds universitet Medicinska fakulteten Lund University Cardiology |
| CorporateAuthor_xml | – name: For the DETO2X-SWEDEHEART Investigators – name: DETO2X-SWEDEHEART Investigators – name: Faculty of Medicine – name: Department of Clinical Sciences, Lund – name: Medicinska fakulteten – name: Sektion II – name: Molekylär kardiologi – name: Kardiologi – name: Section II – name: Lund University – name: Cardiology – name: Molecular Cardiology – name: Institutionen för kliniska vetenskaper, Lund – name: Lunds universitet |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 ADTPV AOWAS DG8 D93 DF2 F1U D95 |
| DOI | 10.1161/CIRCULATIONAHA.118.036220 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic SwePub SwePub Articles SWEPUB Linköpings universitet SWEPUB Umeå universitet SWEPUB Uppsala universitet SWEPUB Göteborgs universitet SWEPUB Lunds universitet |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1524-4539 |
| EndPage | 2762 |
| ExternalDocumentID | oai_swepub_ki_se_481952 oai_portal_research_lu_se_publications_737e0361_29fb_4699_9683_73f603c02116 oai_lup_lub_lu_se_737e0361_29fb_4699_9683_73f603c02116 oai_gup_ub_gu_se_275701 oai_DiVA_org_uu_372939 oai_DiVA_org_umu_154871 oai_DiVA_org_liu_153672 30767504 10_1161_CIRCULATIONAHA_118_036220 00003017-201812110-00005 |
| Genre | Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- .-D .3C .XZ .Z2 01R 0R~ 0ZK 18M 1J1 29B 2FS 2WC 354 40H 4Q1 4Q2 4Q3 53G 5GY 5RE 5VS 6PF 71W 77Y 7O~ AAAAV AAAXR AAGIX AAHPQ AAIQE AAJCS AAMOA AAMTA AAQKA AARTV AASCR AASOK AASXQ AAUEB AAWTL AAXQO ABASU ABBUW ABDIG ABJNI ABOCM ABPMR ABPXF ABQRW ABVCZ ABXVJ ABXYN ABZAD ABZZY ACDDN ACDOF ACEWG ACGFO ACGFS ACILI ACLDA ACOAL ACRKK ACWDW ACWRI ACXJB ACXNZ ACZKN ADBBV ADCYY ADGGA ADHPY AE3 AE6 AEBDS AEETU AENEX AFBFQ AFCHL AFDTB AFEXH AFMBP AFNMH AFSOK AFUWQ AGINI AHMBA AHOMT AHQNM AHQVU AHRYX AHVBC AIJEX AINUH AJCLO AJIOK AJNWD AJZMW AKCTQ AKULP ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AOQMC ASPBG AVWKF AYCSE AZFZN BAWUL BOYCO BQLVK BYPQX C45 CS3 DIK DIWNM DU5 E3Z EBS EEVPB EJD ERAAH EX3 F2K F2L F2M F2N F5P FCALG GNXGY GQDEL GX1 H0~ HLJTE HZ~ IKREB IKYAY IN~ IPNFZ JF9 JG8 JK3 K-A K-F K8S KD2 KMI KQ8 L-C L7B N9A N~7 N~B O9- OAG OAH OBH OCB ODMTH OGEVE OHH OHYEH OK1 OL1 OLB OLG OLH OLU OLV OLY OLZ OPUJH OVD OVDNE OVIDH OVLEI OVOZU OWBYB OWU OWV OWW OWX OWY OWZ OXXIT P2P PQQKQ RAH RIG RLZ S4R S4S T8P TEORI TR2 TSPGW UPT V2I VVN W2D W3M W8F WH7 WOQ WOW X3V X3W XXN XYM YFH YOC YSK YYM YZZ ZFV ZY1 ~H1 AAFWJ AAYXX CITATION ACIJW CGR CUY CVF ECM EIF NPM 7X8 .55 .GJ 1CY 41~ AAEJM ACCJW ADFPA ADNKB ADSXY ADTPV AFFNX AJJEV AJNYG AOWAS BS7 C1A DG8 DUNZO E.X FEDTE FL- FW0 H13 HVGLF H~9 J5H JK8 M18 MVM N4W NEJ N~M OCUKA ODA OHT ORVUJ OUVQU P-K R58 WHG X7M YQJ YXB YYP ZGI ZXP ZZMQN D93 DF2 F1U AAYOK D95 |
| ID | FETCH-LOGICAL-c7615-be05f9b5f50c7e525675e67ef67bc903f85b0462baace884c0a97aa5c92d97e93 |
| ISSN | 0009-7322 1524-4539 |
| IngestDate | Mon Sep 01 03:34:23 EDT 2025 Thu Aug 21 06:50:55 EDT 2025 Thu Jul 03 05:24:02 EDT 2025 Thu Aug 21 06:54:13 EDT 2025 Thu Aug 21 06:43:07 EDT 2025 Thu Aug 21 06:54:15 EDT 2025 Thu Aug 21 06:49:22 EDT 2025 Fri Jul 11 07:59:57 EDT 2025 Thu Apr 03 06:55:33 EDT 2025 Tue Jul 01 04:15:16 EDT 2025 Thu Apr 24 23:10:22 EDT 2025 Fri May 16 03:42:14 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 24 |
| Keywords | heart failure death hospitalization myocardial infarction mortality oxygen inhalation therapy registries |
| Language | English |
| License | 2018 American Heart Association, Inc. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c7615-be05f9b5f50c7e525675e67ef67bc903f85b0462baace884c0a97aa5c92d97e93 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.118.036220 |
| PMID | 30767504 |
| PQID | 2183186822 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | swepub_primary_oai_swepub_ki_se_481952 swepub_primary_oai_portal_research_lu_se_publications_737e0361_29fb_4699_9683_73f603c02116 swepub_primary_oai_lup_lub_lu_se_737e0361_29fb_4699_9683_73f603c02116 swepub_primary_oai_gup_ub_gu_se_275701 swepub_primary_oai_DiVA_org_uu_372939 swepub_primary_oai_DiVA_org_umu_154871 swepub_primary_oai_DiVA_org_liu_153672 proquest_miscellaneous_2183186822 pubmed_primary_30767504 crossref_citationtrail_10_1161_CIRCULATIONAHA_118_036220 crossref_primary_10_1161_CIRCULATIONAHA_118_036220 wolterskluwer_health_00003017-201812110-00005 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2018 |
| PublicationDateYYYYMMDD | 2018-01-01 |
| PublicationDate_xml | – year: 2018 text: 2018 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Circulation (New York, N.Y.) |
| PublicationTitleAlternate | Circulation |
| PublicationYear | 2018 |
| Publisher | by the American College of Cardiology Foundation and the American Heart Association, Inc |
| Publisher_xml | – name: by the American College of Cardiology Foundation and the American Heart Association, Inc |
| References | e_1_3_5_28_2 e_1_3_5_27_2 e_1_3_5_26_2 e_1_3_5_25_2 e_1_3_5_24_2 e_1_3_5_23_2 e_1_3_5_22_2 e_1_3_5_21_2 e_1_3_5_29_2 e_1_3_5_2_2 e_1_3_5_1_2 e_1_3_5_8_2 e_1_3_5_20_2 e_1_3_5_7_2 e_1_3_5_9_2 e_1_3_5_4_2 e_1_3_5_3_2 e_1_3_5_6_2 e_1_3_5_5_2 e_1_3_5_17_2 e_1_3_5_16_2 e_1_3_5_15_2 e_1_3_5_14_2 e_1_3_5_12_2 e_1_3_5_13_2 e_1_3_5_10_2 e_1_3_5_11_2 e_1_3_5_32_2 e_1_3_5_19_2 e_1_3_5_18_2 e_1_3_5_31_2 e_1_3_5_30_2 31207616 - Ann Intern Med. 2019 Jun 18;170(12):JC63 |
| References_xml | – ident: e_1_3_5_20_2 doi: 10.1016/j.ahj.2013.09.022 – ident: e_1_3_5_29_2 doi: 10.1001/jama.2017.11463 – ident: e_1_3_5_26_2 doi: 10.1093/eurheartj/ehy326 – ident: e_1_3_5_19_2 doi: 10.1136/hrt.2010.198804 – ident: e_1_3_5_6_2 doi: 10.1016/S0140-6736(16)31012-1 – ident: e_1_3_5_32_2 doi: 10.1186/1471-2458-11-450 – ident: e_1_3_5_8_2 doi: 10.1016/0002-8703(95)90194-9 – ident: e_1_3_5_18_2 doi: 10.1136/heartjnl-2017–312322 – ident: e_1_3_5_12_2 doi: 10.1093/eurheartj/eht110 – ident: e_1_3_5_28_2 doi: 10.1016/S0140-6736(18)30479-3 – ident: e_1_3_5_22_2 doi: 10.1007/s10654-016-0117-y – ident: e_1_3_5_21_2 doi: 10.1093/eurheartj/ehs184 – ident: e_1_3_5_2_2 doi: 10.1161/CIRCULATIONAHA.117.030798 – ident: e_1_3_5_10_2 doi: 10.1161/01.CIR.52.3.360 – ident: e_1_3_5_7_2 doi: 10.1016/j.jacc.2016.01.069 – ident: e_1_3_5_24_2 doi: 10.1161/CIRCULATIONAHA.117.031664 – ident: e_1_3_5_14_2 doi: 10.1161/CIRCULATIONAHA.114.014494 – ident: e_1_3_5_23_2 doi: 10.1056/NEJMe1709250 – ident: e_1_3_5_31_2 doi: 10.1007/s00134-017-4739-7 – ident: e_1_3_5_25_2 doi: 10.1136/heartjnl-2018–313089 – ident: e_1_3_5_27_2 doi: 10.1111/joim.12716 – ident: e_1_3_5_4_2 doi: 10.1016/j.jacc.2015.10.005 – ident: e_1_3_5_15_2 doi: 10.1016/j.jacc.2006.03.034 – ident: e_1_3_5_3_2 doi: 10.1161/CIR.0000000000000133 – ident: e_1_3_5_1_2 doi: 10.1056/NEJMra1112570 – ident: e_1_3_5_11_2 doi: 10.1016/j.jacc.2010.04.052 – ident: e_1_3_5_13_2 doi: 10.1016/j.jchf.2016.03.026 – ident: e_1_3_5_17_2 doi: 10.1056/NEJMoa1706222 – ident: e_1_3_5_16_2 doi: 10.1136/hrt.2006.112508 – ident: e_1_3_5_9_2 doi: 10.1161/01.CIR.53.3.411 – ident: e_1_3_5_5_2 doi: 10.1093/eurheartj/ehx393 – ident: e_1_3_5_30_2 doi: 10.1016/j.resuscitation.2018.04.027 – reference: 31207616 - Ann Intern Med. 2019 Jun 18;170(12):JC63 |
| SSID | ssj0006375 |
| Score | 2.366914 |
| Snippet | BACKGROUND:In the DETO2X-AMI trial (Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction), we compared supplemental oxygen with ambient... In the DETO2X-AMI trial (Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction), we compared supplemental oxygen with ambient air in... In the DETO2X-AMI trial (Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction), we compared supplemental oxygen with ambient air in... BACKGROUND: In the DETO2X-AMI trial (Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction), we compared supplemental oxygen with... Background: In the DETO2X-AMI trial (Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction), we compared supplemental oxygen with... |
| SourceID | swepub proquest pubmed crossref wolterskluwer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2754 |
| SubjectTerms | acute coronary syndromes Acute Disease Aged Cardiac and Cardiovascular Systems Cardiology and Cardiovascular Disease Clinical Medicine death disease Female guideline heart failure Heart Failure - etiology Heart Failure - mortality hospitalization Hospitalization - statistics & numerical data Humans inhalation intensive statin therapy Kaplan-Meier Estimate Kardiologi Kardiologi och kardiovaskulära sjukdomar Klinisk medicin Male management Medical and Health Sciences Medicin och hälsovetenskap Middle Aged mortality myocardial infarction Myocardial Infarction - pathology Myocardial Infarction - therapy oxygen inhalation therapy Oxygen Inhalation Therapy - adverse effects Proportional Hazards Models Registries Risk Factors size st-segment-elevation supplementation task-force Treatment Outcome |
| Title | Long-Term Effects of Oxygen Therapy on Death or Hospitalization for Heart Failure in Patients With Suspected Acute Myocardial Infarction |
| URI | https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00003017-201812110-00005 https://www.ncbi.nlm.nih.gov/pubmed/30767504 https://www.proquest.com/docview/2183186822 https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-153672 https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-154871 https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-372939 https://gup.ub.gu.se/publication/275701 https://lup.lub.lu.se/record/737e0361-29fb-4699-9683-73f603c02116 oai:portal.research.lu.se:publications/737e0361-29fb-4699-9683-73f603c02116 http://kipublications.ki.se/Default.aspx?queryparsed=id:139760112 |
| Volume | 138 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bb9MwFLbGkCYQQsC4lJs8CfYyZSTOxfFjtQtl2gBBhyZeLMd1umpdMqWNYPwC_hF_j3PiNG1ZgQ3x0Khy7aO457PP8fHnY0JehAHvmZRHjqcVc4JAKydWsFjhLtNCgb3yDAb0D95GncNg7yg8Wlr6McNaKsfJpv628FzJv2gVykCveEr2CppthEIBfAf9whM0DM9L6Xg_z_pOF-bWjZ0pLePd13NogFQKTBeAmwHb6OYh8XxySUh99rKiGHYA6uONXTVAfjpGP97bTKtIjIVWH8vqLCa4pW2NlIKDczB-Rc-m6EhhlDSKnaQ7GBS6vhJs0U0_M5GHPVM07LJuQ1NCchDGCY7tdgjSvhsSSHuYFqY3qg-J7eXg_Z428QSQNCxtmByJKFlezEY05qdfFjhBaNMbNfOzH88AkQWz0y23Gagv2oEI7YCe9lgdKyiNN9FgM3dq_ObSbA_LM_gk8JEjI7nPDVT3JBNpIoNICCmi2IfyNHJ9Dc6RF10j1xmsT9AivD6acosiv8rw3HRnhazVb_Xqt-807xhdWO00qWxvkltfcmRSjE6qgxQz7lD3Drldr2No24LyLlky2T2y2s7UOD89p-u0YhZXWzb3yMpBTeBYJd8byNIasjRPqYUsrSFL84xWkKV5QX-BLE2xDCFLa8jSQUYnkKUIWdpAllaQpVPI0ilk75PD3Z3uVsepLwNxNAev20mMG6YiCdPQ1dyE4Knz0ETcpBFPtHD9NA4TPGidKKVNHAfaVYIrFWrBeoIb4T8gy1memUeEioCzgAcpM6EOwFdRoMso6uHdBEKEoWmReKIJqetM-Xhhy1BWK2ZAxNabD1uH-zZddacNZbG0SmwR1jQ9s-liLtNobaJuCZM77tipzOTlSOL6Be-zYKxFHlocNGLBOEd4N0OLrFtgNL8glLcHn9oyL_pyOCgleDURZ3-pWJ5ixSDmXou8_GPFUuJevy8WC-zDIIKifjWGYIByFwTuLKh49dHWIp8XyLFxClknRzuu5Z3N7HpcUvii3tRFJwOUGSDpAP5HZ24ASntiHWk8GF_iDquSIHpelbLDDR__p94_ITdQso3_PiXL46I0z2BFNE6eV7PPTzlEZMA |
| linkProvider | Geneva Foundation for Medical Education and Research |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Long-Term+Effects+of+Oxygen+Therapy+on+Death+or+Hospitalization+for+Heart+Failure+in+Patients+With+Suspected+Acute+Myocardial+Infarction&rft.jtitle=Circulation+%28New+York%2C+N.Y.%29&rft.au=Jernberg%2C+Tomas&rft.au=Lindahl%2C+Bertil&rft.au=Alfredsson%2C+Joakim&rft.au=Berglund%2C+Ellinor&rft.date=2018&rft.issn=1524-4539&rft.volume=138&rft.issue=24&rft.spage=2754&rft_id=info:doi/10.1161%2Fcirculationaha.118.036220&rft.externalDocID=oai_lup_lub_lu_se_737e0361_29fb_4699_9683_73f603c02116 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-7322&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-7322&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-7322&client=summon |